Online citations, reference lists, and bibliographies.
← Back to Search

First-pass Metabolism Of Cyclosporin By The Gut

J. Kolars, P. Watkins, R. Merion, W. Awni
Published 1991 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Cyclosporin is thought to be exclusively metabolised in the liver. We instilled cyclosporin into the small bowel of 2 patients during the anhepatic phase of liver transplantation; cyclosporin metabolites were readily detected in portal venous blood. Our findings indicate that the small intestine is a major site of cyclosporin breakdown: such intestinal metabolism might help to explain the poor oral bioavailability and drug interactions of cyclosporin.
This paper references
Drug therapy: cyclosporine
B. Kahan (1989)
Body weight control: The physiology, clinical treatment, and prevention of obesity
A. Bender (1987)
Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data.
R. Zaczek (1990)
10.1111/J.1365-2125.1989.TB05396.X
Cyclosporin-erythromycin interaction in renal transplant patients.
S. K. Gupta (1989)
10.1016/0006-8993(89)91467-4
D-, L- and DL-fenfluramine cause long-lasting depletions of serotonin in rat brain
M. Kleven (1989)
Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.
T. Aoyama (1989)
Species differences in the kinetics and metabolism of fenfluramine isomers.
S. Caccia (1982)
10.1016/0140-6736(90)90137-T
Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA
M. R. Lucey (1990)
10.2165/00003088-198611020-00002
Clinical Pharmacokinetics of Cyclosporin
R. Ptachcinski (1986)
10.1038/clpt.1988.87
Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs
T. Kronbach (1988)
10.1172/JCI113156
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.
P. Watkins (1987)
10.1097/00007890-199203000-00021
CYCLOSPORINE METABOLISM BY P450IIIA IN RAT ENTEROCYTES—ANOTHER DETERMINANT OF ORAL BIOAVAILABILITY?
J. Kolars (1992)
10.1093/ACPROF:OSO/9780192620118.001.0001
5-hydroxytryptamine in psychiatry : a spectrum of ideas
M. Sandler (1991)
10.1016/0378-4347(88)80027-6
Optimized high-performance liquid chromatographic method for the analysis of cyclosporine and three of its metabolites in blood and urine.
W. Awni (1988)
10.1016/0041-008X(69)90178-1
Anorexigenic effects of fenfluramine hydrochloride in rats, guinea pigs, and dogs.
R. S. Alphin (1969)
10.1055/S-2008-1040480
Role of cytochromes P450 in drug metabolism and hepatotoxicity.
P. Watkins (1990)
10.1016/S0140-6736(89)91499-2
INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY
B. Guy-grand (1989)



This paper is referenced by
10.1016/0009-9236(95)90067-5
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
D. Gómez (1995)
10.2165/00003495-199550020-00003
Gender Effects in Pharmacokinetics and Pharmacodynamics
R. Z. Harris (2012)
10.1016/S0009-9236(96)90163-0
Erythromycin‐felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice
D. Bailey (1996)
10.1038/clpt.1993.199
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
M. Kinirons (1993)
Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.
M. Paine (1999)
10.1023/A:1006469621561
The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery
H. A. Bardelmeijer (2004)
10.1124/JPET.102.034728
Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4
R. K. Bhardwaj (2002)
In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
T. Prueksaritanont (1997)
10.1067/mcp.2000.104642
Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe
J. Villeneuve (2000)
10.1016/j.addr.2012.09.042
Intestinal drug transporters: an overview.
M. Estudante (2013)
10.1002/HEP.510240407
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
M. Fromm (1996)
10.1016/j.clpt.2004.04.013
Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans
H. Glaeser (2004)
10.1124/dmd.120.090738
Regional Proteomic Quantification of Clinically Relevant Non-Cytochrome P450 Enzymes along the Human Small Intestine
H. Zhang (2020)
10.1016/0006-2952(94)90091-4
Intestinal clearance of H2-antagonists.
Y. Hui (1994)
Study on herb-drug interactions
L. Yang (2009)
10.1080/17425255.2018.1482277
An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling
Saeed Alqahtani (2018)
10.18356/d3cce20a-en
Current trends in
V. Zawar (2010)
10.1016/S0009-9236(96)90162-9
First-pass metabolism of midazolam by the human intestine.
M. Paine (1996)
10.2174/1389200219666181031113505
Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity.
Q. Wu (2019)
10.1002/IBD.3780010107
A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease
W. Sandborn (1995)
10.1016/S0009-9236(96)90023-5
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine
C. M. Stein (1996)
10.1093/BJA/77.1.32
Molecular mechanisms of drug metabolism in the critically ill.
G. Park (1996)
10.1111/j.2042-7158.1997.tb06071.x
Inhibition of Nifedipine Metabolism in Dogs by Erythromycin: Difference between the Gut Wall and the Liver
S. Tsuruta (1997)
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
M. Paine (1997)
10.1006/RTPH.1999.1322
Situations with enhanced chemical risks due to toxicokinetic and toxicodynamic factors.
E. Dybing (1999)
10.2165/00003088-200038020-00002
Effects of the Antifungal Agents on Oxidative Drug Metabolism
K. Venkatakrishnan (2000)
Effects of gemfibrozil and rifampicin on the pharmacokinetics of HMG-CoA reductase inhibitors
C. Kyrklund (2004)
Drug metabolism in human and rat intestine: an 'in vitro' approach
E. G. V. D. Kerkhof (2007)
10.1016/J.JCONREL.2007.02.004
PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
J. L. Italia (2007)
10.1016/0009-9236(95)90168-X
Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine
C. Wu (1995)
10.1016/0006-2952(94)90418-9
Metabolism of lidocaine by rat pulmonary cytochrome P450.
K. Tanaka (1994)
10.1002/chem.201501270
Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport.
U. K. Marelli (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar